Faron Pharmaceuticals Feed

2025-05-23 08:00:00 Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

2025-05-21 08:00:00 Faron Appoints Ralph Hughes as Chief Business Officer (CBO) 2,87 EUR | +4,36% | 1,39 MEUR

2025-05-15 08:00:00 Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress 2,59 EUR | -1,89% | 0,60 MEUR

2025-05-14 15:00:00 Faron Pharmaceuticals Ltd: Grant of Options 2,64 EUR | -1,49% | 0,40 MEUR

2025-05-12 08:00:00 Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session 2,65 EUR | -4,68% | 1,16 MEUR

2025-04-24 08:00:00 Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025 2,42 EUR | -1,02% | 0,39 MEUR

2025-04-17 14:15:00 Holding in Company 2,44 EUR | +6,09% | 3,51 MEUR

2025-04-15 08:10:00 Sisäpiiritieto: Faron julkistaa positiivisia II vaiheen tuloksia hoitoresistentin korkeariskin myelodysplastisen syndrooman hoidossa 2,70 EUR | -7,69% | 4,82 MEUR

2025-04-15 08:00:00 Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome 2,70 EUR | -7,69% | 4,82 MEUR

2025-04-03 08:00:00 Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million 2,50 EUR | -8,61% | 2,61 MEUR

2025-03-27 08:00:00 Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress 2,58 EUR | +5,74% | 0,91 MEUR

2025-03-21 14:15:00 Board Changes 2,30 EUR | -5,93% | 0,61 MEUR

2025-03-21 12:45:00 Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM 2,30 EUR | -5,93% | 0,61 MEUR

2025-03-20 08:00:00 Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected 2,44 EUR | +6,54% | 0,85 MEUR

2025-03-03 13:00:00 Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS 2,10 EUR | +4,48% | 1,09 MEUR

2025-02-28 13:00:00 NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING 2,01 EUR | -0,99% | 0,21 MEUR

2025-02-27 08:30:00 Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS) 2,03 EUR | +1,60% | 0,52 MEUR

2025-02-27 08:15:00 Faron Pharmaceuticals Ltd’s Annual Report 2024 published 2,03 EUR | +1,60% | 0,52 MEUR

2025-02-27 08:00:00 Faron’s Financial Statement Release 1 January to 31 December 2024 2,03 EUR | +1,60% | 0,52 MEUR

2025-02-19 11:00:00 Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025 2,02 EUR | -3,81% | 0,24 MEUR

2025-02-14 13:00:00 Holding(s) in Company 2,04 EUR | -2,40% | 0,28 MEUR

2025-02-11 08:30:00 Change of Broker 1,91 EUR | -1,44% | 0,83 MEUR

2025-02-06 16:00:00 Holding(s) in Company 2,11 EUR | +10,01% | 15,9 MEUR

2025-02-06 08:00:00 Results of the Significantly Oversubscribed Placing 2,11 EUR | +10,01% | 15,9 MEUR

2025-02-05 17:30:00 Proposed Issue and Placing 2,11 EUR | +10,01% | 15,9 MEUR

2025-01-31 08:00:00 Final Patient Identified for the BEXMAB Study 2,04 EUR | -3,33% | 0,73 MEUR

2024-06-05 09:00:00 Proposed REX Retail Offer 1,28 EUR | -2,74% | 1,09 MEUR

2024-06-04 08:00:00 Faron commences a share offering 1,31 EUR | -44,20% | 2,52 MEUR

2024-05-20 09:00:00 Faron Pharmaceuticals julkaisi ensimmäisiä faasin II tuloksia leukemiapotilailla 3,10 EUR | +7,08% | 1,82 MEUR

2024-05-20 08:00:00 Initial positive data from Phase 2 of BEXMAB 3,10 EUR | +7,08% | 1,82 MEUR

2024-05-17 17:00:00 Issuance of warrants

2024-05-16 08:05:00 Founders named European Inventor Award finalists 2,85 EUR | +1,79% | 0,53 MEUR

2024-05-13 08:00:00 Replacement – Board Change 2,41 EUR | -5,68% | 1,27 MEUR

2024-04-30 15:00:00 Update on financial status 1,81 EUR | +2,84% | 0,16 MEUR

2024-04-30 14:00:00 Board Change 1,81 EUR | +2,84% | 0,16 MEUR

2024-04-16 08:00:00 Faron confirms plans under new leadership 1,48 EUR | +2,21% | 0,20 MEUR

2024-04-15 08:00:00 Appointment of Chief Financial Officer 1,45 EUR | +0,84% | 0,09 MEUR

2024-04-08 08:10:00 Approval of Warrant Terms and Conditions 1,52 EUR | 0,00% | 0,12 MEUR

2024-04-08 08:05:00 Decisions of the Board of Directors 1,52 EUR | 0,00% | 0,12 MEUR

2024-04-08 08:00:00 Appointment of Chief Executive Officer 1,52 EUR | 0,00% | 0,12 MEUR

2024-04-05 13:00:00 Results of the Annual General Meeting 1,52 EUR | -2,07% | 0,07 MEUR

2024-04-04 08:00:00 Announcement of Placing 1,55 EUR | -8,40% | 5,26 MEUR

2024-03-28 08:00:00 Issue of Warrants to IPF Funding Update 1,71 EUR | +2,51% | 0,11 MEUR

2024-03-26 11:00:00 Faron´s Annual Report 2023 1,70 EUR | -0,35% | 0,10 MEUR

2024-03-18 10:08:20 Faron Pharmaceuticals julkaisee jälleen rohkaisevia testituloksia verisyöpien hoidossa 2,15 EUR | +20,51% | 0,42 MEUR

2024-03-18 08:00:00 Additional Positive Data from Phase 1 of BEXMAB 2,15 EUR | +20,51% | 0,42 MEUR

2024-03-14 08:00:00 Faron to Host BEXMAB Webcast 1,72 EUR | -7,14% | 0,09 MEUR

2024-03-13 15:00:00 Notice of Annual General Meeting 2024 1,85 EUR | +13,37% | 0,14 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Faron Pharmaceuticals

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden